Investigational drug · Phase 2
SPH5030
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Biliary Tract or Colorectal Cancer With Her2-positive/Mutated.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SPH5030"
First trial start
2024
Jul 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPH5030", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Approved drugs for the same conditions: Colorectal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SPH5030" as an intervention, largest first.
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05245058 · 150 participants (planned) · Start Jan 21, 2022 · Primary completion Dec 21, 2026
Drug: SPH5030 tablets · For: HER2-positive Advanced Solid Tumors
Sites: Hefei, China; Beijing, China; Guangzhou, China · 17 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT06434597 · 60 participants (planned) · Start Jul 17, 2024 · Primary completion Dec 31, 2026
Drug: SPH5030 · For: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Sites: Beijing, China; Changsha, China; Changzhi, China · 30 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT06372223 · 16 participants · Start Mar 4, 2024 · Primary completion Mar 25, 2024
Drug: SPH5030; SPH5030 · For: Advanced Solid Tumor
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy.
Zheng S, Chen R, Zhang L, et al. · Eur J Med Chem 2024
- Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment.
Li D, Tu Y, Jin K, et al. · J Med Chem 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.